Back to Agenda
Session 20: Benefit-Risk
Session Chair(s)
JP Clement, MD
Founder and Principal
JPCC Associates, United States
This session will address the concepts that encompass stakeholder perceptions in the iterative assessment of benefit-risk. Several models of structured benefit-risk assessment, as well as FDA’s current approach to benefit-risk, will be explained. The session will conclude with an introduction to risk communication.
Have an account?